Insmed (NASDAQ: INSM) reports 12-month TPIP OLE results in PAH
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Insmed Incorporated reported 12‑month results from a 24‑month open‑label extension study of once‑daily treprostinil palmitil inhalation powder (TPIP) in 91 patients with pulmonary arterial hypertension who had completed prior TPIP trials. The study is single‑arm and uses baseline values from the Phase 2b lead‑in study.
Patients continuing TPIP and those crossing over from placebo both showed sustained improvements at Month 12, including mean six‑minute walk distance gains of 55.7 meters and 54.1 meters from baseline, and an approximately 60% reduction in NT‑proBNP levels by Month 6 that was maintained at Month 12. About 80% of patients achieved World Health Organization Functional Class I or II, and roughly 65% reached Refined Low Risk status on the REVEAL Lite 2.0 mortality risk score.
Once‑daily TPIP was generally well tolerated through Month 12 at doses up to 1,280 µg. Treatment‑emergent adverse events occurred in 89.0% of patients, serious events in 18.7%, severe events in 16.5%, and adverse events led to discontinuation in 7.7%. There were four deaths, none considered related to TPIP. Insmed states that these findings support continued TPIP development and the ongoing Phase 3 PALM‑PAH trial.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Patients enrolled in OLE: 91 patients
Any treatment-emergent adverse events: 89.0% of patients
Serious TEAEs: 18.7% of patients
+5 more
8 metrics
Patients enrolled in OLE
91 patients
Total number of pulmonary arterial hypertension patients in the TPIP open-label extension
Any treatment-emergent adverse events
89.0% of patients
Proportion of 91 patients experiencing TEAEs through Month 12
Serious TEAEs
18.7% of patients
Share of patients with serious treatment-emergent adverse events in the OLE
TEAEs leading to discontinuation
7.7% of patients
Patients who discontinued the study due to treatment-emergent adverse events
6MWD improvement (continued TPIP)
55.7 meters
Mean change from Phase 2b baseline in six-minute walk distance at Month 12
6MWD improvement (placebo crossed)
54.1 meters
Mean change from Phase 2b baseline in six-minute walk distance at Month 12
NT-proBNP reduction
~60%
Approximate mean reduction from baseline by Month 6, maintained at Month 12
Refined Low Risk REVEAL status
~65% of patients
Proportion of all patients achieving Refined Low Risk REVEAL Lite 2.0 status at Month 12
Key Terms
open-label extension, treprostinil palmitil inhalation powder, six-minute walk distance, N-terminal pro-B-type natriuretic peptide, +2 more
6 terms
open-label extension medical
"12-Month data from the ongoing open-label extension study of treprostinil palmitil"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
treprostinil palmitil inhalation powder medical
"study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily"
A dry inhaled powder that contains a modified form of the drug treprostinil designed to release the active medicine slowly in the lungs when breathed in. It aims to treat diseases of the lung blood vessels by widening those vessels and reducing pressure, similar to a time‑release pill but delivered to the airways. Investors watch it because inhaled, long‑acting formulations can mean less frequent dosing, potentially better patient adherence, distinct safety and efficacy profiles, and a different commercial opportunity than existing therapies.
six-minute walk distance medical
"sustained improvement with TPIP in six-minute walk distance (6MWD)"
Six-minute walk distance (6MWD) is a simple test that measures how far a person can walk on a flat surface in six minutes, used to gauge overall heart and lung function and physical endurance. Investors care because changes in this distance in clinical studies can show whether a treatment meaningfully improves patients’ daily abilities, which influences regulatory approval, clinical value, market demand, and potential reimbursement — similar to measuring how much farther a car can drive after an upgrade.
N-terminal pro-B-type natriuretic peptide medical
"N-terminal fragment pro-B-type natriuretic peptide (NT-proBNP) concentration"
A blood marker released when the heart is under stress, N-terminal pro-B-type natriuretic peptide (NT-proBNP) helps doctors detect and monitor heart failure and other cardiac strain. Think of it as a dashboard warning light: higher levels signal worse heart function. For investors, NT-proBNP matters because it is widely used in clinical trials, guides treatment decisions, and influences demand for diagnostics, therapies, and reimbursement in the cardiovascular market.
REVEAL Lite 2.0 medical
"clinically meaningful improvement in REVEAL Lite 2.0 score at Month 12"
treatment-emergent adverse events medical
"treatment-emergent adverse events (TEAEs) occurred in 89.0% of patients"
Events or symptoms that either appear for the first time or get worse after a patient starts a treatment; think of new or intensified side effects that show up once medicine or a medical device is used. Investors watch these closely because they affect whether a therapy can gain regulatory approval, be prescribed widely, or face legal and commercial setbacks—similar to how early customer complaints can sink a new product’s prospects.
FAQ
What did Insmed (INSM) report from the 12-month TPIP OLE study in PAH?
Insmed reported that once-daily TPIP produced sustained improvements at 12 months in exercise capacity, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 risk scores in 91 PAH patients previously enrolled in TPIP lead-in studies.
How many patients were included and retained on TPIP in Insmed’s OLE study?
The TPIP open-label extension enrolled 91 patients with pulmonary arterial hypertension from prior TPIP studies. Insmed reports that 91% of OLE patients remained on TPIP treatment at Month 12, indicating substantial on‑therapy retention over the first study year.
What efficacy outcomes did TPIP show at 12 months in Insmed’s PAH OLE?
At Month 12, patients had mean six-minute walk distance gains of 55.7 m (continued TPIP) and 54.1 m (placebo crossed), about a 60% reduction in NT-proBNP, ~80% in WHO Functional Class I or II, and roughly 65% in Refined Low Risk REVEAL Lite 2.0 status.
What safety profile for TPIP did Insmed highlight in the 12-month OLE data?
Once-daily TPIP was described as generally well tolerated up to 1,280 µg. 89.0% of patients had treatment-emergent adverse events, 18.7% had serious events, 7.7% discontinued due to events, and four deaths occurred, none judged related to TPIP. Common events included headache and cough.
How did REVEAL Lite 2.0 risk scores change with TPIP in Insmed’s OLE study?
Insmed reports that TPIP led to clinically meaningful improvements in REVEAL Lite 2.0 scores, a validated mortality risk tool in PAH. Mean scores improved by 2.0 points (continued TPIP) and 1.4 points (placebo crossed), with about 65% of all patients reaching Refined Low Risk status at Month 12.
What are Insmed’s next steps for TPIP after these 12-month OLE results?
Insmed states that the 12‑month OLE findings support continued TPIP development, including the ongoing Phase 3 PALM-PAH randomized, double-blind, placebo-controlled trial in PAH and plans for a broader registrational program across four indications, including PH-ILD, PPF, and IPF.
Did patients who switched from placebo to TPIP in Insmed’s OLE see benefit?
Yes. Patients who crossed from placebo to TPIP achieved similar outcomes to those who continued TPIP across efficacy measures at Month 12, including six-minute walk distance, NT-proBNP, WHO Functional Class, and REVEAL Lite 2.0 risk scores, based on Insmed’s reported analyses.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
(Zip Code)
|
|
|
(Address of principal executive offices)
|
Registrant’s telephone number, including area code: (908 ) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 7.01 —
|
Regulation FD Disclosure.
|
On July 16, 2026, Insmed Incorporated (the “Company”) issued a press release announcing 12-month safety and efficacy data from its ongoing open-label extension study of treprostinil palmitil inhalation powder in patients with
pulmonary arterial hypertension (the “OLE Study”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The Company will host a conference call to discuss the 12-month data of the OLE Study on July 16, 2026, at 8:00 a.m., Eastern Time, and a live webcast of
the call will be available through the investor relations section of the Company’s website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
ITEM 9.01 —
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press release issued by Insmed Incorporated on July 16, 2026.
|
|
|
99.2
|
Insmed Incorporated July 16, 2026 12-Month OLE Study Presentation
|
|
|
104
|
Cover Page Interactive Date File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Dated: July 16, 2026
|
INSMED INCORPORATED
|
|
|
By:
|
/s/ Michael A. Smith
|
|
|
Name:
|
Michael A. Smith
|
|
|
Title:
|
Chief Legal Officer and Corporate Secretary
|
|
Exhibit 99.1
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients
with Pulmonary Arterial Hypertension
–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary
Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0–
–Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12–
–TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were
Permitted in the OLE Study–
–These OLE Data,
Combined with Once-Daily Inhaled Administration, Reinforce TPIP’s Potential to Become the Prostanoid of Choice for Patients with PAH–
–Insmed to Host
Investor Call Thursday, July 16, 2026, at 8:00 a.m. ET–
BRIDGEWATER, N.J., July 16, 2026 -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class
therapies to transform the lives of patients facing serious diseases, today announced positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in
patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term safety, tolerability, and effectiveness of TPIP over 24 months in
patients who completed the lead-in TPIP PAH studies.
"These data from our ongoing OLE study with TPIP represent an important milestone in our efforts to fully
harness the potential of treprostinil and provide meaningful benefit to patients with pulmonary arterial hypertension," said Gene Sullivan, M.D., Chief Product Strategy Officer of Insmed. “In this analysis, TPIP demonstrated sustained improvement across all efficacy endpoints and was well tolerated with no newly identified safety signals, and notably, patients who switched from placebo to TPIP in the OLE study
achieved similar clinical benefit. These data, coupled with the statistically significant and clinically meaningful results from our Phase 2b randomized study, demonstrate TPIP's potential to become the prostanoid of choice for PAH patients,
and we remain excited to be advancing our Phase 3 PALM-PAH study."
12-Month Results from the Ongoing OLE Study with TPIP in Patients with PAH
Results for secondary efficacy endpoints demonstrated sustained improvement with TPIP in six-minute walk distance (6MWD), N-terminal fragment pro-B-type natriuretic
peptide (NT-proBNP) concentration, and World Health Organization (WHO) Functional Class, as well as a clinically meaningful improvement in REVEAL Lite 2.0 score at Month 12. Patients in the Placebo Crossed group (N=31) showed similar outcomes to
patients in the TPIP Continued group (N=60) across all efficacy measures at Month 12.
The results at Month 12 were as follows:
| • |
Mean improvement from baseline for 6MWD was +55.7 meters for the TPIP Continued group and +54.1 meters for the Placebo Crossed group.
|
| • |
NT-proBNP concentration was reduced by approximately 60% in both groups with geometric mean ratios [GMR] to baseline of 0.40 and 0.41 in TPIP Continued and Placebo Crossed, respectively.
|
| • |
WHO Functional Class I or II was achieved in 78.3% of TPIP Continued group and 80.6% of Placebo Crossed group patients, and more than 25% of patients across both groups achieved WHO Functional
Class I.
|
| • |
Mean REVEAL Lite 2.0 score improved 2.0-points from baseline for the TPIP Continued group and 1.4-points from baseline for the Placebo Crossed group. Approximately 65% of all patients achieved
Refined Low Risk status, which is associated with a less than 5% estimated risk of mortality at three years and an approximately 7% risk of clinical worsening at one year.
|
"Pulmonary arterial hypertension is one of the most devastating diseases we face as clinicians, and these results from the ongoing TPIP OLE study give us genuine reason
for optimism,” said Dr. Raymond Benza, M.D., F.A.C.C., FAHA, FACP, Phase 2b PAH study Steering Committee Member, George M. and Linda H. Kaufman Academic Chair of Cardiology, Sentara Health. “The REVEAL Lite 2.0 risk score provides a powerful,
non-invasive way to track disease trajectory. Previous REVEAL Lite 2.0 validation showed that a 1-point score improvement reduces risk of mortality by 23% and reduces the risk of clinical worsening by 21%. Here we saw that patients on TPIP
averaged a greater than 1-point improvement from baseline, which is really meaningful for patients. Sustained improvements of this magnitude, alongside gains in exercise capacity and Functional Class, provide a strong clinical rationale to
advance this therapy into Phase 3 development."
Results for the primary endpoint of safety & tolerability showed that once-daily TPIP therapy was generally well tolerated with no newly identified safety signals
at doses up to 1,280 µg through Month 12. Of the 91 patients in the study, treatment-emergent adverse events (TEAEs) occurred in 89.0% of patients; serious TEAEs were observed in 18.7% of patients; and severe TEAEs were observed in 16.5% of
patients in the study. TEAEs leading to study discontinuation were experienced by 7.7% of patients. There were four deaths, none of which were considered related to TPIP treatment. The most common TEAEs through Month 12 occurring in 5.0% or more
of all patients were headache (28.6%), cough (15.4%), nasopharyngitis (14.3%), diarrhea (11.0%), upper respiratory tract infection (9.9%), bronchitis (7.7%), dizziness (6.6%), epistaxis (6.6%), nausea (6.6%), anemia (5.5%), influenza (5.5%), and
pneumonia (5.5%).
The 12-Month OLE findings support the continued clinical development of TPIP and the recent initiation of PALM-PAH, a Phase 3, randomized, double-blind,
placebo-controlled trial evaluating once-daily TPIP in patients with PAH over 24 weeks. The primary endpoint of PALM-PAH is change in 6MWD, with additional assessments of safety, tolerability, and overall efficacy. Insmed plans to publish the
12-Month results from this OLE study in the future. Topline results from the Phase 2b study of TPIP in patients with PAH were previously reported in June 2025.
Conference Call Information
Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, July
16, 2026, to discuss the TPIP OLE study results. Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.) or +1 (646) 307-1963 (International) and referencing access code 2033335. The
call will also be webcast live on the Company's website at www.insmed.com.
A replay of the conference call will be accessible approximately one hour after its completion through July 23, 2026, by dialing (800) 770-2030 (U.S. and Canada) or +1
(609) 800-9909 (International) and referencing access code 2033335. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com.
About TPIP
Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an
ester bond to a 16-carbon chain. Developed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being evaluated as a once-daily therapy for the treatment of patients with PAH, pulmonary hypertension associated
with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). TPIP is administered in a capsule-based inhalation device. TPIP is an
investigational drug product that has not been approved for any indication in any jurisdiction.
About the TPIP Open-Label Extension Study
The 24-month open-label extension (OLE) study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) was designed to
evaluate the long-term safety, tolerability, and effectiveness of TPIP administered once daily in patients who completed the lead-in TPIP PAH studies. The OLE is being conducted at 45 sites globally and enrolled 91 eligible patients. The study included a 3-week blinded titration period followed by open-label treatment. Patients who received TPIP in the lead-in studies (TPIP Continued) received their achieved dose of TPIP;
patients who received placebo in the lead-in studies (Placebo Crossed), or had delayed rollover, underwent titration starting at 80 µg once daily up to their target dose (i.e., 640 µg or
highest tolerated dose) over three weeks. Further escalation up to 1,280 µg was permitted after the initial titration period at investigator discretion to optimize clinical benefit. Outcomes were evaluated against the Phase 2b lead-in study in
PAH (NCT05147805) pre-randomization baseline values for relevant measurements.
The primary endpoint is evaluating long-term safety and tolerability, including treatment-emergent adverse events (TEAEs) and TEAEs by severity. Secondary endpoints
include change from lead-in study pre-randomization baseline in six-minute walk distance (6MWD), N-terminal fragment pro-B-type natriuretic peptide (NT-proBNP) concentration, World Health Organization (WHO) Functional Class, REVEAL Lite 2.0
score, and additional exploratory measures over 24 months of treatment.
About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a serious, progressive, rare disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood
pressure in the pulmonary arteries. The most common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue, and weakness. It is estimated that approximately 35,000 patients in the U.S., 40,000 patients in the EU5
(France, Germany, Italy, Spain, and the UK), and 15,000 patients in Japan have been diagnosed with the disease. Untreated PAH can be debilitating and often fatal.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing
serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases—as well as cutting-edge drug discovery
focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The
Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as
one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to
learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Forward-looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates,"
"believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.
The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties
and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or
indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risk that the full data set from the OLE study of TPIP in PAH (the “Study”) or data generated in further clinical
trials of TPIP will not be consistent with the interim results of the Study; the risk that data from the Study, which is conducted in a single-arm, open-label design without a concurrent placebo control group, may not be predictive of, or may
differ materially from, results obtained in the Phase 3 PALM-PAH randomized, double-blind, placebo-controlled trial; the risk that the Study’s efficacy endpoints, which are secondary and exploratory in nature, may overestimate or otherwise not
accurately reflect the true treatment effect of TPIP; failure to successfully conduct future clinical trials for TPIP, such as the Company’s planned Phase 3 program for TPIP, including due to the Company's potential inability to enroll or retain
sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; development of unexpected safety or efficacy concerns related to TPIP; failure of third parties on which the Company is
dependent to manufacture sufficient quantities of TPIP for clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business or agreements with the
Company; failure to obtain regulatory approval for TPIP; inaccuracies in the Company's estimates of the size of the potential markets for TPIP or in data the Company has used to identify physicians; expected rates of patient uptake, duration of
expected treatment, or expected patient adherence or discontinuation rates, if TPIP is approved; inability of the Company or the Company's third-party manufacturers to comply with regulatory requirements related to TPIP; the Company's inability
to obtain adequate reimbursement from government or third-party payors for TPIP or acceptable prices for TPIP, if approved; restrictions or other obligations imposed on the Company by agreements related to TPIP and failure to comply with the
Company’s obligations under such agreements; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; the strength and enforceability of the Company’s intellectual property
rights or the rights of third parties; and the cost and potential reputational damage resulting from litigation to which the Company may become a party, including product liability claims.
The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature,
forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the
Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission
(SEC).
The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company
disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
Exhibit 99.2
